Abstract: OBJECTIVE To explore the relationship between matrix metalloproteinase-9（MMP-9）, monocyte chemoattractant protein-1（MCP-1） and growth-regulated oncogene α（GRO-α） in cervical secretions and genital tract infection as well as pregnancy outcomes of premature rupture of membranes（PROM） patients. METHODS A total of 69 PROM pregnant women who were treated in obstetrics and gynecology department of Henan Provincial Hospital of Traditional Chinese Medicine from Mar 2019 to Mar 2022 were assigned as the PROM group, meanwhile, 50 healthy pregnant women were chosen as the control group. The pathogens in vaginal secretions and cervical secretions such as Ureaplasma urealyticum（UU）, bacterial vaginosis（BV）, vulvovaginal candidiasis（VVC） were tested, the levels of MMP-9, MCP-1 and GRO-α in cervical secretions were detected. The values of cervical secretion MMP-9, MCP-1 and GRO-α in prediction of genital tract infection were evaluated, and the levels of cervical secretion MMP-9, MCP-1 and GRO-α as well as the mother and infant outcomes were observed and compared among the PROM pregnant women with different types of infection. RESULTS The incidence rates of BV, UU infection and VVC as well as the total infection rate were higher in the PROM group than in the control group（P＜0.05）. The levels of cervical lesion MMP-9, MCP-1 and GRO-α of the PROM group were higher than those of the control group（P＜0.05）; the levels of cervical secretion MMP-9, MCP-1 and GRO-α of the PROM patients complicated with genital tract infection were higher than those of the patients without infection（P＜0.05）. In the PROM group, the levels of cervical secretion MMP-9, MCP-1 and GRO-α of the patients with mixed infections of BV, UU and VVC were higher than those of the patients without infection（P＜0.05）. The sensitivity of the joint detection of cervical secretion MMP-9, MCP-1 and GRO-α was 97.10% in prediction of genital tract infection in the PROM pregnant women, with the specificity 94.10%. The total incidence rate of adverse neonatal outcomes and adverse maternal outcomes of the patients complicated with genital tract infection was higher than that of the patients without infection（P＜0.05）. The genital tract infection was the influencing factor for the adverse mother and infant outcomes（P＜0.05）. CONCLUSION The genital tract infection in the PROM patients is associated with the adverse mother and infant outcomes, which may affect the mother and infant outcomes by upregulating the levels of MMP-9, MCP-1 and GRO-α.